Hat mitgewirkt an:
-
The interplay between BCR/ABL and PROM-1/CD133 influences drug response and cell fate decision in Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL)
-
p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia
-
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
-
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I